Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and ...

Equillium Inc (NASDAQ:EQ) stock plunged 12.4% following the company’s announcement that it will integrate cryptocurrency ...

Investing.com -- Equillium Inc (NASDAQ: EQ) stock tumbled 12.4% after the biotechnology company announced plans to integrate cryptocurrency into its treasury reserve strategy, a significant deviation ...

Investing.com -- Equillium Inc (NASDAQ:EQ)股价暴跌12.4%，此前这家生物技术公司宣布计划将加密货币纳入其财政储备策略，这与其开发自身免疫和炎症疾病治疗方案的核心业务有显著偏离。 这家总部位于圣地亚哥的公司透露，将开始持有数字货币作为其财务和增长目标的一部分，同时继续推进其生物技术使命。首席执行官Bruce Steel表示，此举是为了"多样化、流动性和长期 ...

As the U.S. markets react to recent economic uncertainties, including weak job reports and tariff concerns, investors are reassessing their strategies amid fluctuating indices. In this context, penny ...

Shares of CommScope Holding Company, Inc. COMM +44.4% Get Free Report rose sharply in pre-market trading. The Wall Street Journal reported Sunday that Amphenol is nearing a deal for CommScope’s ...

DelveInsight's KIT Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a ...

Equillium, Inc. (NASDAQ:EQ – Get Free Report) traded down 6.1% on Wednesday . The company traded as low as $0.37 and last traded at $0.38. 27,135 shares traded hands during trading, a decline of ...

Equillium Inc. is advancing EQ-504, a potent aryl hydrocarbon receptor (AhR) modulator acquired through the acquisition of Ariagen Inc., a company that was majority owned by Equillium’s largest ...

Equillium Inc. research and ratings by Barron's. View 0A4D revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.

Shares of Equillium, Inc. (EQ) have been struggling lately and have lost 52.2% over the past week. However, a hammer chart pattern was formed in its last trading session, which could mean that the ...